300 related articles for article (PubMed ID: 30005773)
1. Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.
Moore-Smith L; Forero-Torres A; Stringer-Reasor E
Surg Clin North Am; 2018 Aug; 98(4):773-785. PubMed ID: 30005773
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
3. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
Liedtke C; Rody A
Rev Recent Clin Trials; 2017; 12(2):73-80. PubMed ID: 28270088
[TBL] [Abstract][Full Text] [Related]
5. Local therapy for triple-negative breast cancer: a comprehensive review.
Grubb W; Young R; Efird J; Jindal C; Biswas T
Future Oncol; 2017 Aug; 13(19):1721-1730. PubMed ID: 28776394
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives.
Carbognin L; Furlanetto J; Vicentini C; Nortilli R; Pilotto S; Brunelli M; Pellini F; Pollini GP; Bria E; Tortora G
Anticancer Agents Med Chem; 2015; 15(1):15-25. PubMed ID: 25329488
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
8. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Agrawal LS; Mayer IA
Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
11. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer.
Connor CS; Kimler BF; Mammen JM; McGinness MK; Wagner JL; Alsop SM; Ward C; Fabian CJ; Khan QJ; Sharma P
J Surg Oncol; 2015 Feb; 111(2):198-202. PubMed ID: 25266871
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
Wein L; Loi S
Breast; 2017 Aug; 34 Suppl 1():S27-S30. PubMed ID: 28668293
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
[TBL] [Abstract][Full Text] [Related]
14. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
15. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.
Agostinetto E; Eiger D; Punie K; de Azambuja E
Curr Oncol Rep; 2021 Mar; 23(5):57. PubMed ID: 33763756
[TBL] [Abstract][Full Text] [Related]
16. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
17. AKT1
Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
[TBL] [Abstract][Full Text] [Related]
18. Triple negative breast cancer in Asia: An insider's view.
Wang C; Kar S; Lai X; Cai W; Arfuso F; Sethi G; Lobie PE; Goh BC; Lim LHK; Hartman M; Chan CW; Lee SC; Tan SH; Kumar AP
Cancer Treat Rev; 2018 Jan; 62():29-38. PubMed ID: 29154023
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
Man VC; Cheung PS
Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
